Stockhub

Senhwa Biosciences, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

25 September 2022

  • curprev 20:5220:52, 25 September 2022 95.149.241.133 talk 1,659 bytes +1,659 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and special pharmaceutical ingredients. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; and CX-5461 CA, which is in phase I clinical trials in patients with solid tumors..."
Retrieved from "https://stockhub.co/research/Senhwa_Biosciences,_Inc."